J Clin Oncol 2011 Jun 1
International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.
Related Questions
Would you offer it for positive margins? NCCN says to consider adjuvant radiation for pT3-T4 or pN0-2. Is there sufficient evidence for adjuvant radia...
New answer by Radiation Oncologist at Springfield Clinic (May 22, 2017)
Local-regional recurrence for patients with ≥pT3 disease after radical cystectomy is a significant problem (1) and warrants consideration of adjuvant radiatio...
Do you think adjuvant nivolumab should be the new standard of care based on current CM274 DFS data? If OS turns out to be no different, will you still...
New comment by Medical Oncologist at University of Utah Huntsman Cancer Institute ( March 3, 2022)
FDA approved in August 2021.
Surgical data suggests improved survival with pelvic lymphadenectomy and is recommended by NCCN guidelines, however the same is not seen with RT data....
New comment by Radiation Oncologist at Varian Medical Systems/Allegheny health network ( September 6, 2024)
Favor nodal RT if otherwise suitable for surgery akin to surgical management with the potential for neoadjuvant chemo.
If comorbidities or age don’t allow surgery...
Would you offer definitive radiation/chemoradiation if he is refusing cystectomy?
New comment by Radiation Oncologist at Mon Health ( October 14, 2024)
What dose would you give to the whole bladder and partial bladder?